US Patent

US8236292 — Liquid depot formulations

Method of Use · Assigned to Camurus AB · Expires 2027-01-10 · 1y remaining

Vulnerability score 88/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects liquid depot formulations that can form a liquid crystalline phase structure when mixed with an aqueous fluid.

USPTO Abstract

The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.

Drugs covered by this patent

Subutex (BUPRENORPHINE) · Purdue Pharma Lp

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3619`	—	Subutex
`U-3619`	—	Subutex
`U-3619`	—	Subutex
`U-3619`	—	Subutex
`U-3619`	—	Subutex
`U-3619`	—	Subutex
`U-3619`	—	Subutex

Patent Metadata

Patent number: US8236292
Jurisdiction: US
Classification: Method of Use
Expires: 2027-01-10
Drug substance claim: No
Drug product claim: Yes
Assignee: Camurus AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.